Results: SBRT treatment: maximum small bowel and duodenum dose-volume constraints were exceeded in 5/30 (16.7%) and 2/30 (6.7%), respectively. Dose to OARs was: small bowel: Dmax 31.5-40.5 Gy, V30 0.2-13.4 cc; duodenum: Dmax 35.7-36.6 Gy, V30 2.1-3.7 cc. SBRS treatment: maximum small bowel and duodenum dosevolume constraints were exceeded in 2/21 patients (9.5%) and 1/21 patient (4.7%), respectively. Dose to OARs was: small bowel: Dmax 15.6-16.3 Gy, V12 1.7-8.5 cc; duodenum Dmax 16.0 Gy, V12 0.1 cc. With a median follow up of 24 months after SBRT and 18 months after SBRS, no early or late severe toxicity was observed in patients in whom constraints were not respected.
Material and Methods:
In a dose escalation (Phase I) study, previously irradiated patients were enrolled in two different arms depending on treatment site and previous dose: 1) retreatment with previous dose > 60 Gy or retreatment of pancreatic and pelvic tumors, 2) retreatment with previous dose < 60 Gy. SBRT was delivered in 5 fractions with static 3D technique (4 non-coplanar beams) or dynamic arc (VMAT). The dose was prescribed at the isocenter. The Planning Target Volume (PTV) was defined as the GTV + 5-15 mm margin. According to the study arm, the first cohort of 6 patients received a dose of 20 or 25 Gy, and subsequent cohorts of patients received doses up to 40 Gy. The dose limiting toxicity (DLT) was defined as any acute and late toxicity Grade ≥ 3. The MTD was defined a s the dose level with 2/6 or 4/12 DLT.
Results:
From September 2004 to December 2014, 51 patients (M/F: 27/24; median age 65, range 44-87), previously irradiated with doses of 30 to 87 Gy (median dose 50 Gy) were enrolled, after 4-228 months from the first treatment (median 11 months). Sixty-six lesions were treated (23 primary lesions or relapses, 43 lymphadenopathies) mainly from gynecological tumors (30%), followed by gastrointestinal tumors (26%) and prostatic tumors (17%). Nineteen of the 66 lesions were in the neck or chest, 22 in the abdomen and 25 in the pelvis. With a median follow-up of 19 months (3-104), an overall response rate of 81% (Complete Response: 55%, Partial Response: 26%), with only 3% of disease progression was recorded. At 40 Gy dose-level, only 1 patient showed DLT (cutaneous fistula in the sacral region). Two-year local control was 75% and 2-year metastasis-free survival was 30%.
Conclusion: SBRT treatment in 5 fractions up to a dose of 40 Gy is well tolerated in previously irradiated patients. This dose escalation protocol is still ongoing (Table 1) .
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Extra-cranial radiosurgery in oligometastatic disease: a dose escalation study (Destroy-2). F. Deodato 
Material and Methods:
Based on a Dose Escalation study (Phase I), oligometastatic patients were enrolled in 4 different arms depending on site and treatment purpose: 1) liver metastases, 2) lung metastases, 3) lymph node metastases or liver or lung metastases with a prolonged local control purpose, 4) bone metastases (non-vertebral). Dose was prescribed according to the Rosel protocol (V100 >95%, V90 >99% and Dmax <140% of the prescription) with dynamic S364 ESTRO 35 2016 ______________________________________________________________________________________________________ volumetric intensity modulated arc technique (VMAT). The Planning Target Volume (PTV) was defined as the GTV plus a personalized Internal Margin and a 3 mm Set -up Margin. Based on the study arm, the first cohort of 6 patients received a dose of 12-26 Gy, and the subsequent cohorts of patients received doses up to 30 Gy. The dose limiting toxicity (DLT) was defined as any acute and > Grade 3 late toxicity (CTC-AE v. 4.03). In case of 2/6 or 4/12 DLT in the analyzed cohort, this dose was considered as MTD.
Results: From August 2010 to April 2015 92 patients were enrolled (M/F: 50/42; median age: 67 years (40-93); range: 40-93) and 142 lesions were treated (bone: 47, lung: 39, nodes: 33, and liver: 23) mainly from prostatic (28%), gastrointestinal (25%), breast (21%), and gynecological (8%) tumors. With a median follow-up of 11 months (2-58 ), overall response rate was 70 % (CR: 47%, PR: 23%), with 15% stable disease and only 4% of progressive disease (15 lesions (11%) not evaluable for response at the time of the analysis). No DLT was recorded. Two-year local control at was 77% and 2-year metastases-free survival was 34%. Two-year overall survival was 78%.
Conclusion: SBRS is well tolerated up to a dose of 30 Gy. The dose escalation protocol is ongoing (Table) . 
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Material and Methods:
A total of 225 vertebral segments in 154 patients treated with palliative radiotherapy from Sep 2011 to Aug 2013 were included for analysis. VCF was defined as occurrence or progression of collapse deformity within treated vertebral segments. Each segment was scored by SINS. In addition to 6 SINS components, we also evaluated the impact of paraspinal tumor extension, epidural extension, tumor origin, performance status, and radiotherapy-related factors on VCF risk. Recursive partitioning analyses (RPA) was used to identify optimal classification of risk groups.
Results:
The median follow-up was 8.5 months. The 6-month and 12-month VCF-free probability was 83.3% and 77.3%, and median survival was 10 months. Multivariate analysis identified paraspinal tumor extension (P= 0.03) and baseline vertebral body collapse (P<0.001) were independent predictors for VCF. All SINS criteria except body collapse were not significant for VCF. The RPA defined 3 risk groups. The lowest risk group (n= 96) were vertebrae with less than 50% body involved by tumor and no collapse. The intermediate risk group (n= 90) were vertebrae with more than 50% body involved and no collapse, or vertebrae with body collapse and no paraspinal tumor extension. The highest risk group (n= 39) were vertebrae with body collapse and paraspinal extension. The 6-month VCF-free probability for each groups were 93.5%, 84.9%, and 53.7%, respectively (P<0.001). According to the SINS classification, the 6-month VCF-free probabilities were 91.9% (stable group, n=78), 81.9% (potentially unstable group, n= 122), and 62.8% (unstable group, n=25) (P<0.001).
Conclusion:
Not all the components of SINS were significant predictors of VCF. It is feasible to estimate VCF by the simpler RPA stratification. Material and Methods: 640 cases of symptomatic bone metastases treated with EBRT were analyzed. The primary tumor sites were breast (419), prostate (52), lung (50), renal (37), colon (13), melanoma (8), sarcomas (7) and others including bladder, thyroid, uterus, carcinoid (54). The lesions of spine and pelvis predominated (48% and 30% correspondingly). Pathological fractures in treatment area were observed in 72,3% for spinal metastases and in 22,2% for long bones lesions. The average pain intensity was 2,2 by the four-point verbal scale and proved significantly lower for carcinoid tumors. Treatment schedules included 2, 3 and 4 fractions of 6,5 Gy and standard treatment schedule with 23 fractions of 2 Gy.
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Results:
The average follow-up period was 70 months. Overall effectiveness of EBRT -96,1%. Complete response rate (CRR) -59,1%. The pain relapse rate -8,7%. CRR for standard treatment schedule was 77,4% and significantly decreased from 64,4% to 47,9% and 43,6% for 4, 3 and 2 fractions of 6,5 Gy correspondingly (p<0,05). There was no correlation between treatment schedules and pain relapse rate. CRR in patients with low initial pain intensity was 87,3%, with moderate pain -59,8% and intense pain -42% (p<0,01). CRR for spine and pelvis lesions was 63,4% and 59,3%, for long bones metastases -48,3% and significantly decreased for sacrum isolated metastases -27,8% (р<0,01). The frequency of pathological fractures in treatment area detected no correlation with CRR. High radiosensitivity was revealed for bone metastases of carcinoid with CRR 100%, melanoma -75%, breast cancer -64%, prostate cancer -59,6% and sarcomas -57,1%. Bone metastases of lung, colon, and renal cancer turned to be radioresistance (44%, 30,1% and 27% correspondingly). Analysis of variance (ANOVA) revealed several factors affecting CRR: tumor primary site (p<0,001), total dose (p<0,001), initial pain intensity (p<0,001), localization of metastases in skeleton (p<0,02). In the multifactorial analysis MANOVA tumor primary site and pain intensity before radiotherapy were the only independent prognostic factors of CRR.
Conclusion:
Tumor primary site, initial pain intensity, total dose, localization of metastases in skeleton are clinical predictors of radiosensitivity of bone metastases, they significantly affect the CRR.
